South Dakota Board of Pharmacy Wholesale Distributors; Active, in Good Standing As of October 5, 2018 This Document May Be Used As a Primary Source Verification
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Report Title Election Report for Cases Closed Region(S) (Report Defaults
Report Title Election Report for Cases Closed Region(s) Election Held Date Closed Date (Report Defaults) Between (Report Defaults) and (Report Defaults) Between 10/1/2016 and 9/30/2017 12:00:00 AM Case Type Case Name Labor Org 1 Name State City (Report Defaults) (All Choices) (All Choices) (Report Defaults) (Report Defaults) Election Report for Cases Closed NLRB Elections - Summary Time run: 10/16/2017 8:16:17 AM Case Type No. of Elections Percent Won by Union Total Employees Eligible to Vote Total Valid Votes for Total Valid Votes Against Total Elections 1391 65.0% 92,653 43,607 31,642 RC 1193 71.0% 79,750 37,631 26,806 RD 172 32.0% 12,319 5,757 4,573 RM 26 30.0% 584 219 263 NLRB Elections with 1 Labor Organization Time run: 10/16/2017 8:16:17 AM Region Case Number Case Name Case City State Election Number Valid Votes Labor Org 1 Name Stipulated Certification of Certification Case Closed Type Held Date of Votes for / Consent Representative of Results Closed Reason Eligible Against Labor / Directed Date (Win) Date (Loss) Date Voters Org 1 01, 34 01-RC-181492 GREEN LINE GROUP INC. RC DEDHAM 9/30/2016 211 57 93 INTERNATIONAL Directed WON 12/21/2016 Certific. of BROTHERHOOD OF Representative MA ELECTRICAL WORKERS LOCAL 1228, AFL-CIO 01, 34 01-RC-182252 RENZENBERGER, INC. RC WORCHESTER 9/12/2016 26 2 7 UNITED STEEL, PAPER AND Stipulated WON 10/6/2016 Certific. of FORESTRY, RUBBER, Representative MA MANUFACTURING, ENERGY, ALLIED INDUSTRIAL AND SERVICE WORKE 01, 34 01-RC-182433 J's Associates, LLC RC Springfield 9/8/2016 12 2 8 Area Trades Council of New Stipulated WON 10/3/2016 Certific. -
S P O T L I G H T Pa R T I C I Pa N
SPOTLIGHT PARTICIPANTS 12 Copyright © 2019 Mercer (US) Inc. All rights reserved. ORGANIZATION LISTING 3M (Minnesota Mining & Manufacturing) Atlas Energy Group LLC City of Overland Park, KS Cleveland Indians Baseball Co. A&E Television Networks Auburn University City of Winston-Salem, NC CliftonLarsonAllen, LLP A.O. Smith Corporation Automatic Data Processing California Health Care Foundation CMA CGM (America) LLC American Automobile Association, Inc., The Automobile Club of Southern California Cabot Oil & Gas Corporation CNH Industrial America LLC Accenture LLP AXA XL Cactus Feeders, Inc. CNO Financial Group Accudyne Industries, LLC Badger Meter, Inc. Cadmus Holding Company CNOOC Petroleum U.S.A. Inc. Advance Auto Parts Baltimore Orioles California Endowment, The CNX Resources ADVICS North America, Inc. Bank of the Ozarks, Inc. California ISO Colorado Rockies Baseball Club AECOM Building & Construction Bank of New York Mellon California Wellness Foundation Cobb Electric Membership Corporation AECOM Enterprise Baptist Health - FL Cambia Health Solutions (Regence Group) Coca-Cola Company, Inc., The AECOM Management Services Crestline Hotels & Resorts, LLC Canadian Imperial Bank of Commerce COG Operating, LLC Aera Energy Services Company Barnes & Noble, Inc. Canadian National Cognizant Technology Solutions Corporation Affinity Federal Credit Union BASF Corporation Canadian Pacific Railway CohnReznick LLP AgReserves Inc. Basin Electric Power Co-op Canadian Solar, Inc. Colby College Agri Beef Company Bates College Capital Group Companies, Inc., The Colonial Group, Inc. American International Group, Inc. (AIG) Battelle Memorial Institute Capital One Financial Corporation Columbia Sportswear Company Aimbridge Hospitality Baylor College of Medicine CarMax Auto Superstores, Inc. Columbia University American Institutes for Research BB&T Corporation Carilion Clinic Columbus McKinnon Corporation Air Liquide USA Blue Cross Blue Shield of Kansas Carrix, Inc. -
Discovering and Developing Innovative New Medicines Designed to Extend and Enhance the Quality of Human Life
® Discovering and developing innovative new medicines designed to extend and enhance the quality of human life. 2011 Annual Report Company Profile Athersys is an international, clinical-stage biotechnology company that is focused on developing novel and proprietary best-in-class therapies designed to treat significant unmet medical needs that extend and enhance the quality of human life. The Company is developing MultiStem®, a patented, adult-derived “off-the- shelf” stem cell product platform for multiple disease indications in the inflammatory & immune, neurological and cardiovascular disease areas. Current clinical-stage programs include: an ongoing Phase II trial to treat inflammatory bowel disease (partnered with Pfizer); an ongoing Phase II trial to treat damage from ischemic stroke; a recently completed Phase I trial to treat damage from acute myocardial infarction (heart attack); and a recently completed Phase I trial to prevent or reduce GvHD. MultiStem® Production Process Athersys has forged a network of strategic Scalable & Consistent alliances and collaborations with leading pharmaceutical and biotechnology Isolate Material “Off-the-shelf” Product with from Qualified Commercial Scalability Thaw & Administer companies, as well as world- Adult Donor (No tissue matching– renowned research and clinical Lot Release & Product allogeneic product) Characterization Testing Hundreds of thousands institutions in the United to millions of doses States and Europe to PRODUCT STERILITY obtained per donor further develop its Cell Isolation -
Corporate Ghg Inventorying and Target Setting Self-Assessment: V1.0
APPENDIX Corporate GHG Inventorying and Target Setting Self - Assessment : V1.0 Development and Methodology April 2020 APPENDIX: CORPORATE GHG INVENTORYING AND TARGET SETTING SELF-ASSESSMENT: V1.0 Purpose of this Self-Assessment and How it Can Lead to Action Companies are often in a stronger position to improve their greenhouse gas (GHG) management efforts once they understand their relative performance compared to their peers. In response to stakeholder interest, this self-assessment is designed to help companies estimate, at a high level, how their GHG inventorying and target-setting approaches compare to large peer companies representing different industry sectors. Once companies estimate how their key GHG measurement and target-setting efforts compare to their peers, they can evaluate, in greater detail, how other companies approach GHG inventorying and target setting. Helping companies locate their GHG management efforts within the broader market may spur competition, garner internal support for widening the scope of their GHG inventories or setting more aggressive GHG reduction targets, and prioritize resources to implement GHG reduction activities. • Entry-level: For companies beginning to address their GHG emissions, this resource aims to help them identify which inventorying and target-setting actions reflect common business practices today and provide them with a roadmap for developing their own inventories and setting targets. • Intermediate: For companies further along their sustainability journey, this self- assessment can validate more advanced inventorying and target-setting behaviors that position them to deepen GHG emission reductions. • Advanced: For leading companies, this resource can also validate their efforts and encourage them to explore implementing more cutting edge GHG management efforts, eventually pushing such innovations into the mainstream and sharing practices with others. -
A Day in the Life of PHMC 2005 Annual Report What a Difference a Day Makes!
Philadelphia Health Management Corporation A day in the life of PHMC 2005 annual report What a difference a day makes! As I head home from work each evening, I find comfort in knowing that staff from PHMC and its affiliates have reached out to thousands of people since the day began. We believe it’s important to reach people where they are, so every day, we’re in community centers, schools, churches, and people’s homes—wherever we need to be to serve the region’s most vulnerable. In 2005, we were fortunate to bring some unique programs into our network of services: · The PHMC Care Clinic, formerly known as the St. Joseph’s Care Clinic, brings vital medical care to people living with HIV and AIDS in North Philadelphia. · The Bridge began managing the new Parkside E-3 Power Center in West Philadelphia, part of a Philadelphia Youth Network initiative that focuses on empowerment, education, and employment for out-of-school youth and youth returning from the juvenile justice system. · The Joseph J. Peters Institute (JJPI) started an innovative screening and counseling program for Philadelphia grade school children who act in sexually inappropriate ways. · The National Nursing Centers Consortium (NNCC) started its popular STUDENTS RUN Philly Style Program, which mentors Philadelphia students through running programs. · The Health Promotion Council (HPC) expanded its nutrition education work. In addition to their work in the School District of Philadelphia, HPC started working with the North Penn., Wissahickon and Souderton school districts in Montgomery County to fight obesity through promoting healthy eating and healthy lifestyles. -
2010 Annual Report
2010 AnnuAl RepoRt Air Products Celebrating the Innovation of the Past and Its Promise for the Future Financial Highlights 6% 8% Merchant Gases United States 21% • 21% • • Tonnage Gases • Europe Consolidated Consolidated 41% Electronics and Asia • 39% • Sales by Performance Materials Sales by Business Segment Destination • Canada/Latin America/ROW • Equipment and Energy 32% 32% Millions of dollars, except per share 2010 2009 Change For the Year Sales $9,026 $8,256 9% Operating income 1,389 846 64% Operating income (A) 1,485 1,185 25% Net income attributable to Air Products 1,029 631 63% Capital expenditures (A) 1,298 1,475 (12)% Return on capital employed(A) 12.4 % 10.6 % Return on average Air Products shareholders’ equity (B) 19.9 % 13.3 % Operating margin 15.4 % 10.3 % Operating margin(A) 16.5% 14.3% Per Share DollarS Diluted earnings 4.74 2.96 60% Diluted earnings(A) 5.02 4.06 24% Dividends 1.92 1.79 7% Book value 25.94 22.68 14% at Year enD Air Products shareholders’ equity $5,547 $4,792 Shares outstanding (in millions) 214 211 Shareholders 8,300 8,600 Employees (C) 18,300 18,900 (A) Amounts are non-GAAP measures. See pages V and VI for reconciliation to GAAP results. (B) Calculated using income and five-quarter average Air Products shareholders’ equity from continuing operations. (C) Includes full- and part-time employees from continuing and discontinued operations. return on air Products Shareholders’ equity Sales earnings per Share Percentage using income and Air Products Billions of dollars Dollars—diluted basis shareholders’ equity from continuing operations 2010 19.9 2010 9.0 2010 4.74 2009 13.3 2009 8.3 2009 2.96 2008 20.1 2008 10.4 2008 4.15 2007 19.5 2007 9.1 2007 4.64 2006 15.1 2006 7.9 2006 3.18 Air Products | 2010 Annual Report Our Businesses Merchant Gases Industrial and medical customers throughout the world depend on our oxygen, nitrogen, argon, helium, hydrogen, and medical and specialty gases for a wide array of applications. -
Sheffield Teaching Hospitals NHS Foundation Trust Procurement
Sheffield Teaching Hospitals NHS Foundation Trust 07-JAN-2019 14:46:09 Procurement Transparency Payments December-2018 Supplier Value Paid 365 HEALTHCARE 2,730.00 3B TRAINING LTD 4,332.00 3M UNITED KINGDOM PLC 48.78 3M UNITEK UK (ORTHODONTIC PRODUCTS) 1,913.84 7 HILLS LEISURE TRUST 9,332.37 A & S DENTAL 196.56 A ALGEO LTD 31.36 A BOWNES WEBSTER 169.76 A CRAVEN 19.84 A CUMBERLIDGE LTD 4,780.56 A DAY 234.00 A FORRESTER 2,532.30 A GANNAWAY 30.56 A GRAFTON 1,398.90 A HOGG 100.00 A HOOGKAMER 65.77 A HOWARD 129.20 A J HURDLEY 39.10 A L CLINICIAN LIMITED 4,282.00 A LITTLEWOOD 32.00 A LITTLEWOOD 14.40 A M TIME SERVICES 112.68 A MARSHALL 568.40 A MAZAI 5,701.00 A P MACKIE 310.40 A R M ANDRZEJOWSKI 364.00 A RIDSDALE 7,873.86 A SLATER 260.91 A SOMERVILLE LTD 88.37 A SWAIN 15.60 A TAYLOR 29.00 A W BENT LTD 327.26 A WOOD 355.83 A WRIGHT 1,310.08 A&F SPRINKLERS LTD 302.40 A. GAGE OPTICIANS LTD 39.10 AAH PHARMACEUTICALS LTD 1,113,707.10 ABATRON LTD 346.18 ABBOTT LABORATORIES LTD 4,229.46 ABBOTT MEDICAL UK LTD 141,181.20 ABBOTT VASCULAR 48,466.80 ABBVIE LTD 17,765.18 ABILITY HANDLING LTD 482.98 AC MAINTENANCE LTD 5,206.80 ACCIDENT & EMERGENCY AGENCY LIMITED 792.56 Page 1 of 36 Supplier Value Paid ACCORD FLOORING LTD 5,780.92 ACE JANITORIAL SUPPLIES LIMITED 5,159.34 ACORN INDUSTRIAL SERVICES LTD 331.55 ACROSTAK 2,061.60 ACTION ON HEARING LOSS 99.67 ACTIVE DOCUMENTS LTD 2,094.00 ACUMED LTD 3,833.88 ADAM ROUILLY LTD 985.20 ADARE SEC LIMITED 197.90 ADEC DENTAL UK LTD 1,375.56 ADECCO UK LTD 32,195.88 ADEPT LOCUMS LTD 398.35 ADMIRAL DENTAL LABORATORY LTD 181.00 -
Creating Stakeholder Value Creating Stakeholder Value
8446 Annual Report 2011_Annual Report 2011 15/03/2012 16:27 Page FC1 Shire plc Annual ReportShire 2011 Shire plc Annual Report 2011 Creating stakeholder value Creating stakeholder value Effective treatments and services Commitment to superior treatments Improved public for their patients health and societal value Better lives for patients Superior clinical Brave culture driving evidence and clear innovation to deliver economic benefits value to all Return to enable further investment shire.com 8446 Annual Report 2011_Annual Report 2011 15/03/2012 16:27 Page IFC1 Shire plc Annual Repo Shire trademarks The following are trademarks either owned or licensed by Shire plc or companies within the Shire Group (the “Group” or the “Company”) which are the subject of trademark registrations in certain territories, or which are owned by third parties as indicated and referred to in this Annual Report: ADDERALL XR® (mixed salts of a single entity amphetamine) AGRYLIN® (anagrelide hydrochloride) APLIGRAF® (trademark of Organogenesis, Inc. (“Organogenesis”)) APRISO® (trademark of Salix Pharmaceuticals, Ltd. (“Salix”)) ASACOL® (trademark of Medeva Pharma Suisse AG (used under license by Warner Chilcott Company, LLC (“Warner Chilcott”))) ATRIPLA® (trademark of Bristol Myers Squibb Company (“BMS”) and Gilead Sciences, Inc. (“Gilead”)) BERINERT P® (trademark of Aventis Behring GmbH) ® CALCICHEW range (calcium carbonate with or without vitamin D3) CARBATROL® (carbamazepine extended release capsules) CEREZYME® (trademark of Genzyme Corporation (“Genzyme”)) -
Post Conference Report
Europe's leading industry update for all clinical development outsourcing professionals 10th Annual Congress and Exhibition 20 11 Leadership for successful clinical partnerships 15-18 November 2011, Cité Centre de Congrès, Lyon, France POST CONFERENCE REPORT • Record attendance for 2011, over 900+ clinical professionals registered to attend • Most comprehensive agenda , over 95+ hours researched interviews conducted • 150 speakers and 70+ practical case studies presented the latest clinical development in the industry • Largest ever group of Vice Presidents, Directors and Heads of Clinical with multi-million Euro purchasing power • Over 350 different companies attended across 31 countries • Partnerships in Clinical Trials Congress and Exhibition continues to be the market leading event for decision makers to attend • 87% of delegates were from Europe • Overall conference experience has been rated 4 out 5 amongst our attendees Participation Statistics Country Representation 20 11 Function Representation 20 11 Western Europe 48% General Managers 25% Vice President 5% Northern Europe 32% Business Development 19% CEO 4% USA 8% Clinical Operations 17% Account Directors 3% Eastern Europe 6% Outsourcing 12% Data Management 2% Southern Europe 4% Logistics Managers 11% Medical Directors 2% Rest of the World 2% Other 6% Alliance 1% Contract Research 5% www.ct-partnerships.com To register: Call: +44 (0) 20 7017 7481 Fax: +44 (0) 20 7017 7823 Email: [email protected] Reasons why PCT remains THE leading clinical conference to attend in -
A Special Thank You to Our Bionj BIO 2015 Host Committee Members!
A Special Thank You to Our BioNJ BIO 2015 Host Committee Members! Nicole Adams, Chromocell Corporation Geert Cauwenbergh, PhD, Dr. Med. Sc., RXi Pharma Sam Alexander, Pavese-McCormick Agency, Inc. Jean Chang, New Jersey Business Action Center Emil Andrusko, Benchworks Paul Chew, MD, Sanofi Domenick Argento, Merck Sharp & Dohme Corp. John Clarke, Cardinal Partners Chris Asakiewicz, PhD, Stevens Institute of Technology Steven Cohen, Morgan, Lewis & Bockius LLP Didi Asistin, Ontario Ministry of Economic Development, Mary Coleman, Agile Therapeutics Trade and Employment Linda Coles Kauffman, New Jersey Business Action Center Solomon Babani, Covance Karen Coviello, WithumSmith+Brown, PC Kim Baez, Helsinn Therapeutics (US), Inc. Kathleen Coviello, New Jersey Economic Development Richard Bagger, Celgene Corporation Authority Jane Baj, PTC Therapeutics, Inc. Irene Crespo, New Jersey Business Action Center Clara Barreneche, Catalonia Trade & Investment ACC10 NY Tony delCampo, Hackensack University Medical Center Gil Bashe, Makovsky + Company, Inc. Pamela Demain, MBA, CLP, Merck & Co., Inc. Brian Batchelder, Imclone Systems/Eli Lilly and Company Bill DeStefano, USI Insurance Services, LLC Patti Becton, Accenture Charles-Henry Dion, UBIFRANCE North America – Boston Office Thad Bench, Benchworks Debra Duffy, PhR, Elusys Therapeutics, Inc. Gina Bencivengo, NJEDA Regina Dutkowski, d3 Medicine Donna Bernard, BDO USA, LLP Jeff Elton, Accenture Kenneth Blank, PhD, Rowan University Bob Esposito, CPA, M.Ace, EisnerAmper, LLP Keith Bostian, PhD, Kean University Eddie Evans, NPS Pharmaceuticals Taryn Bostjanic, CPA, WithumSmith+Brown, PC Karla Ewalt, Princeton University Cheryl Braunstein, Helsinn Therapeutics (US), Inc. Bonnie Featherstone, BonaFide Staffing, LLC Michele Brown, Choose New Jersey Fred Feiner, Yankee Public Relations Linda Burns, Helsinn Therapeutics (US), Inc. Allison Finnegan, American Express Meetings & Events Michele Cahoone , VWR International, LLC Kit Ford, Taiho Oncology, Inc. -
SHIRE PLC (Exact Name of Registrant As Specified in Its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PLC (Exact name of registrant as specified in its charter) Jersey (Channel Islands) 98-0601486 (State or other jurisdiction of incorporation or (I.R.S. Employer Identification No.) organization) 5 Riverwalk, Citywest Business Campus, Dublin +353 1 429 7700 24, Republic of Ireland (Address of principal executive offices and zip code) (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depositary Shares, each representing three NASDAQ Global Select Market Ordinary Shares 5 pence par value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) 1 Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes [X] No [ ] Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes [ ] No [X] Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. -
2020 ANNUAL REPORT Statement of Intentions the Leadingage 1
W�'�� changing our stripes 2020 ANNUAL REPORT Statement of Intentions The LeadingAge 1. To carry out our mission in ways that are always Quality First Elements ethical and in the expressed spirit of our stated of Quality mission. Dunwoody Village participates in the 2. To create an atmosphere of caring that treats all LeadingAge Quality First program, which residents in a dignified manner respecting helps organizations to achieve excellence individuality, privacy and personal choices. in aging services and earn public trust. By endorsing the Quality First principles, 3. To create health and wellness programs that serve Dunwoody pledges to work in partnership residents along the full continuum of care. with consumers and the government to 4. To support a quality management program that create an environment of high-quality care identifies, develops and implements and service. The ten elements of quality are: ongoing performance improvement projects. • Commitment 5. To cultivate teamwork in providing distinctive • Governance and Accountability high quality services. • Leading-Edge Care and Services 6. To provide a homelike and welcoming environ- • Community Involvement ment that is safe and secure. • Continuous Quality Improvement 7. To support our mission in a cost-efficient and • Human Resources Development effective manner. • Consumer-Friendly Information 8. To provide charitable Personal Care services to a • Consumer Participation limited number of qualified individuals, in keeping • Research Findings and Education with the vision of our founder, William Hood • Public Trust and Consumer Confidence Dunwoody. 9. To promote and develop strong community affilia- tions through residents, employees, and Trustees. 10. To create an atmosphere of growth and opportunity in order to attract and maintain employees who are committed to our Core Values of Teamwork, Respect, Integrity, Compassion, and Quality.